CXCR2 and hepatocellular carcinoma: According to tumor type, CXCR2 overexpression predicted poor OS for patients with hepatocellular carcinoma (HR = 1.60; 95% CI = 1.28–2.01; P < 0.001), esophageal cancer (HR = 2.26; 95% CI = 1.65–3.11; P < 0.001), gastric cancer (HR = 1.98; 95% CI = 1.56–2.51; P < 0.001), renal cell carcinoma (HR = 1.92; 95% CI = 1.27–2.90; P = 0.002), non-small cell lung cancer (HR = 1.56; 95% CI = 1.22–2.01; P < 0.001) and others tumor type (HR = 2.04; 95% CI = 1.43–2.92; P < 0.001) (Figure 3).